Sepsis and the Role of Activated Protein C

Tazbir, Janice
December 2004
Critical Care Nurse;Dec2004, Vol. 24 Issue 6, p40
Academic Journal
Discusses the role of activated protein C (APC) in sepsis. Sources of infection leading to sepsis; Pathophysiology of sepsis; Result of a study that evaluated the use of recombinant human APC in treating sepsis; Limitations to the use of recombinant human APC. INSET: Case Study.


Related Articles

  • Canadian Association of General Surgeons Evidence Based Reviews in Surgery. 8. Efficacy and safety of recombinant human activated protein C for severe sepsis. Barkun, Jeffrey; Christou, Nicolas V.; Barkun, J. S. T.; Cina, C.; Fitzgerald, G. W. N.; Henteleff, H. J. A.; MacRae, H. M.; McLeod, R. S.; Richard, C. S.; Taylor, M. C.; Webber, E. M.; McKenzíe, M. E. // Canadian Journal of Surgery;Dec2003, Vol. 46 Issue 6, p468 

    Objective: To find out whether activated recombinant protein C reduces the death rate from all causes at 28 days among patients with severe sepsis. Design: A randomized, doubleblind, placebo-controlled trial. Setting: Multicentre; 164 centres in 11 countries. Patients: The study comprised 1690...

  • Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis. Bernard, Gordon R.; Vincent, Jean-Louis; Laterre, Pierre-Francois; LaRosa, Steven P.; Dhainaut, Jean-Francois; Lopez-Rodriguez, Angel; Steingrub, Jay S.; Garber, Gary E.; Helterbrand, Jeffrey D.; Ely, E. Wesley; Fisher, Charles J. // New England Journal of Medicine;03/08/2001, Vol. 344 Issue 10, p699 

    Background: Drotrecogin alfa (activated), or recombinant human activated protein C, has antithrombotic, antiinflammatory, and profibrinolytic properties. In a previous study, drotrecogin alfa activated produced dose-dependent reductions in the levels of markers of coagulation and inflammation in...

  • Finally a treatment for sepsis? Saunders, Carol S. // Patient Care;9/30/2000, Vol. 34 Issue 18, p12 

    Deals with the results of a clinical trial investigating recombinant human activated protein C for the treatment of severe sepsis. Stoppage of the third phase of the trial; Proposed product name.

  • Increasing evidence that the risks of rhAPC may outweigh its benefits. Eichacker, Peter Q.; Natanson, Charles // Intensive Care Medicine;Mar2007, Vol. 33 Issue 3, p396 

    The article analyzes the risks and benefits of the use of recombinant human activated protein C (rhAPC) to control severe sepsis. Surveys conducted since the approval of rhAPC in 2001 found that the risk of bleeding during clinical use might be greater than was observed in the original phase-3...

  • The clinical and functional relevance of microparticles induced by activated protein C treatment in sepsis.  // Critical Care;2011, Vol. 15 Issue 3, p10356 

    The article presents a study on the role of activated protein C (APC) circulating microparticles (MP) in sepsis. It says that APC activates endothelial protease-activated receptor 1 (PAR1), inducing anti-apoptotic and anti-inflammatory properties that can improve patient outcome. It states that...

  • New players in the sepsis-protective activated protein C pathway. Ruf, Wolfram // Journal of Clinical Investigation;Sep2010, Vol. 120 Issue 9, p3084 

    Recombinant activated protein C (aPC) improves the survival of patients with severe sepsis, but the precise molecular and cellular targets through which it mediates this effect remain incompletely understood. In this issue of the JCI, Kerschen et al. show that endothelial cell protein C receptor...

  • Severe Sepsis – A New Treatment with Both Anticoagulant and Antiinflammatory Properties. Matthay, Michael A. // New England Journal of Medicine;03/08/2001, Vol. 344 Issue 10, p759 

    The article presents the opinion of the author on an article presenting the results of a clinical trial of severe sepsis, in this issue of the Journal. According to the author, the large clinical trial showed that recombinant human activated protein C significantly reduced mortality in patients...

  • Drotrecogin Alfa (Activated) in Septic Shock. Hollander, Judd E.; Nayyar, Vineet; Solano, Thomas; Thompson, B. Taylor; Ranieri, V. Marco // New England Journal of Medicine;9/6/2012, Vol. 367 Issue 10, p967 

    Several letters to the editor are presented in response to articles in previous issues including V. M. Ranieri et al's study titled "The Prospective Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis and Septic Shock (PROWESS-SHOCK) published in the May 31, 2012 issue.

  • Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administration. Mann, Henry J.; Demmon, Sarah L.; Boelk, Debra A.; Payne, Cynthia A.; Effron, Mark B.; Rajagopalan, Natarajan; Williams, Mark D.; Beck, Gregory M.; Gopalrathnam, Ganapathy // American Journal of Health-System Pharmacy;12/15/2004, Vol. 61 Issue 24, p2664 

    Purpose. The physical and chemical compatibility of drotrecogin alfa (activated) (recombinant human activated protein C) during simulated Y-site administration with drugs commonly used to treat patients with severe sepsis was determined. Methods. Thirty-four drugs were investigated for visual...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics